Journal Publications (text)

Journal Publications (text)                                                               

(Last updated 03 August 2020)

 

2020 publications

 

First-line HIV treatment outcomes following the introduction of integrase inhibitors in UK guidelines: a cohort study. 

El Bouzidi KEL, Jose S, Phillips AN, Pozniak A, Ustianowski A, Gompels M, Winston A, Schaap A, Dunn DT, Sabin CA; UK CHIC Study.

AIDS 2020 Jun 8. doi: 10.1097/QAD.0000000000002603. Online ahead of print.

 

Incidence and risk factors for tuberculosis among people with HIV on antiretroviral therapy in the UK.

Van Halsema CL, Okhai H, Hill T, Sabin CA; UK Collaborative HIV Cohort (UK CHIC) Study.

AIDS. 2020 Jun 4. doi: 10.1097/QAD.0000000000002599. Online ahead of print.

 

Continuation of emtricitabine/lamivudine within combination antiretroviral therapy following detection of the M184V/I HIV-1 resistance mutation.

Stirrup OT, Asboe D, Pozniak A, Sabin CA, Gilson R, Mackie NE, Tostevin A, Hill T, Dunn DT, UK HIV Drug Resistance Database and the UK Collaborative HIV Cohort.

HIV Med 2020; 21:309-321. doi: 10.1111/hiv.12829. Epub 2020 Jan 11.

 

 

2019 publications

 

Virological outcomes of boosted protease inhibitor-based first-line ART in subjects harbouring thymidine analogue-associated mutations as the sole form of transmitted drug resistance.

Geretti AM, White E, Orkin C, Tostevin A, Tilston P, Chadwick D, Leen C, Sabin C, Dunn DT; UK HIV Drug Resistance Database and UK CHIC Study.

J Antimicrobial Chemother 2019; 74:746-53. doi: 10.1093/jac/dky468.  PMID: 30544247

 

Associations between baseline characteristics, CD4 cell count response and virological failure on first-line efavirenz + tenofovir + emtricitabline for HIV.

Stirrup OT, Sabin CA, Phillips AN, Williams I, Churchill D, Tostevin A, Hill T, Dunn DT; UK HIV Drug Resistance Database and the UK Collaborative HIV Cohort.

J Virus Erad 2019: 5:204-211. PMID: 31754443

 

Effectiveness of Transmitted Drug Resistance Testing Before Initiation of Antiretroviral Therapy in HIV-Positive Individuals. 

Lodi S, Günthard HF, Gill J, Phillips AN, Dunn D, Vu Q, Siemieniuk R, Garcia F, Logan R, Jose S, Bucher HC, Scherrer AU, Reiss P, van Sighem A, Boender TS, Porter K, Gilson R, Paraskevis D, Simeon M, Vourli G, Moreno S, Jarrin I, Sabin C, Hernán MA.

J Acquir Immune Defic Syndr. 2019 Nov 1;82(3):314-320. doi: 10.1097/QAI.0000000000002135.  PMID: 31609929    

HIV CAUSAL

 

Effect Estimates in Randomized Trials and Observational Studies: Comparing Apples With Apples. 

Lodi S, Phillips A, Lundgren J, Logan R, Sharma S, Cole SR, Babiker A, Law M, Chu H, Byrne D, Horban A, Sterne JAC, Porter K, Sabin C, Costagliola D, Abgrall S, Gill J, Touloumi G, Pacheco AG, van Sighem A, Reiss P, Bucher HC, Montoliu Giménez A, Jarrin I, Wittkop L, Meyer L, Perez-Hoyos S, Justice A, Neaton JD, Hernán MA; INSIGHT START Study Group and the HIV-CAUSAL Collaboration. 

Am J Epidemiol. 2019 Aug 1;188(8):1569-1577. doi: 10.1093/aje/kwz100.  PMID: 31063192

 

Emulating a trial of joint dynamic strategies: An application to monitoring and treatment of HIV-positive individuals. 

Caniglia EC, Robins JM, Cain LE, Sabin C, Logan R, Abgrall S, Mugavero MJ, Hernández-Díaz S, Meyer L, Seng R, Drozd DR, Seage Iii GR, Bonnet F, Le Marec F, Moore RD, Reiss P, van Sighem A, Mathews WC, Jarrín I, Alejos B, Deeks SG, Muga R, Boswell SL, Ferrer E, Eron JJ, Gill J, Pacheco A, Grinsztejn B, Napravnik S, Jose S, Phillips A, Justice A, Tate J, Bucher HC, Egger M, Furrer H, Miro JM, Casabona J, Porter K, Touloumi G, Crane H, Costagliola D, Saag M, Hernán MA. 

Stat Med. 2019 Jun 15;38(13):2428-2446. doi: 10.1002/sim.8120. Epub 2019 Mar 18.  PMID: 30883859

HIV CAUSAL

 

Long-term virological suppression on first-line efavirenz + tenofovir + emtricitabine/lamivudine for HIV-1. 

Long-Term Virological Suppression Working Group for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. 

AIDS. 2019 Mar 15;33(4):745-751. doi: 10.1097/QAD.0000000000002126.  PMID: 30829745

 

Are European HIV cohort data within EuroCoord representative of the diagnosed HIV population?  Vourli G, Pharris A, Cazein F, Costagliola D, Dabis F, Del Amo J, Delpech V, Díaz A, Girardi E, Gourlay A, Gunsenheimer-Bartmeyer B, Hernando V, Nikolopoulos G, Porter K, Rosińska M, Sabin C, Suligoi B, Supervie V, Wit F, Touloumi G. 

AIDS. 2019 Jan 27;33(1):133-143. doi: 10.1097/QAD.0000000000002034.  PMID: 30289806

EuroCoord

 

 

2018 publications

 

Chronic kidney disease risk in African and Caribbean populations with HIV.

Jose S, Hamzah L, Jones R, Williams D, Winston A, Burns F, Phillips AN, Sabin CA, Post FA;UK CHIC study.

J Infect Dis 2018; 218:1767-1771.

 

A continuum of HIV care describing mortality and loss to follow-up; a longitudinal cohort study.

Jose S, Delpech V, Howarth A,  Burns F, Hill T, Porter K, Sabin CA; UK CHIC Study Steering Committee.

Lancet HIV 2018. Jun;5(6):e301-e308. doi: 10.1016/S2352-3018(18)30048-1. PMID: 29893243

 

The use of funnel plots with regression as a tool to visually compare HIV treatment outcomes between centres adjusting for patient characteristics and size: a UK Collaborative HIV Cohort study.

Gompels M, Michael S, Jose S, Hill T, Trevelion R, Sabin CA, May MT.

HIV Med 2018; 19:386-394. doi: 10.1111/hiv.12604. Epub 2018 Apr 14.  PMID: 29656588

 

Global trends in CD4 cell count at the start of antiretroviral therapy: collaborative study of treatment programs.

IeDEA and COHERE Cohort Collaborations.

Clin Infect Dis 2018; 66:893-903. doi: 10.1093/cid/cix915.  PMID: 29373672

 

Risk factors and outcomes for the Q151M and T69 insertion HIV-1 resistance mutations in historic UK data.

Stirrup OT, Dunn DT, Tostevin A, Sabin CA, Pozniak A, Asboe D, Cox A, Orkin C, Martin F, Cane P; UK HIV Drug Resistance Database; UK Collaborative HIV Cohort.

AIDS Res Ther 2018; 15:11. doi: 10.1186/s12981-018-0198-7.  PMID: 29661246

 

Estimation of delay to diagnosis and incidence in HIV using indirect evidence of infection dates.

Stirrup OT, Dunn DT.

BMC Med Res Methodol 2018; 18:65. doi: 10.1186/s12874-018-0522-x. PMID: 29945571

 

The association between detected drug resistance mutations and CD4+ T-cell decline in HIV-positive individuals maintained on a failing treatment regimen.

Schultze A, Paredes R, Sabin C, Phillips AN, Pillay D, Mackie N, Castagna A, Chadwick D, Falconer K, Geretti AM, Post FA, Hill T, Kirk O, Pozniak A, Nelson M, Tostevin A, Dunn D, Lundgren J, Cozzi-Lepri A.

Antivir Ther 2018; 23:105-116. doi: 10.3851/IMP3178. PMID: 28627486

 

Effect of immediate initiation of antiretroviral treatment on the risk of acquired HIV drug resistance.

Lodi S, Gunthard HF, Dunn D, Garcia F, Logan R, Jose S, Bucher HC, Scherrer AU, Schneider MP, Egger M, Glass TR, Reiss P, van Sighem A, Boender TS, Phillips AN, Porter K, Hawkins D, Moreno S, Monge S, Paraskevis D, Simeon M, Vourli G, Sabin C, Hernan MA, HIV-CAUSAL Collaboration.

AIDS 2018; 32:327-335. doi: 10.1097/QAD.0000000000001692. PMID:  29135583

 

Commonly prescribed antiretroviral therapy regimens and incidence of AIDS-defining neurological conditions.

Caniglia EC, Phillips A, Porter K, Sabin CA, Winston A, Logan R, Gill J, Vandenhende MA, Barger D, Lodi S, Moreno S, Arribas JR, Pacheco A, Cardoso SW, Chrysos G, Gogos C, Abgrall S, Costagliola D, Meyer L, Seng R, van Sighem A, Reiss P, Muga R, Hoyos SP, Braun D, Hauser C, Barrufet P, Leyes M, Tate J, Justice A, Hernán MA. (HIV-CAUSAL Collaboration)

J Acquir Immune Defic Syndr 2018; 77:102-109. doi: 10.1097/QAI.0000000000001562.  PMID: 28991888

 

Non-Hodgkin lymphoma risk in adults living with HIV across five continents. 

AIDS-defining Cancer Project Working Group of IeDEA, COHERE in EuroCoord.

AIDS. 2018 Nov 28;32(18):2777-2786. doi: 10.1097/QAD.0000000000002003. PMID: 30234606

  

 

2017 publications

 

Hepatitis B, hepatitis C and mortality among HIV-positive individuals.

Thornton AC, Jose S, Bhaghani S, Chadwick D, Dunn D, Gilson R, Main J, Nelson M, Rodger A, Taylor C, Youssef E, Leen C, Gompels M, Kegg S, Schwenk A, Sabin C: UK Collaborative HIV Cohort (UK CHIC) steering committee.

AIDS 2017; 31:2525-2532.

 

Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: an observational cohort study.

O'Connor J, Smith C, Lampe FC, Johnson MA, Chadwick DR, Nelson M, Dunn D, Winston A, Post FA, Sabin C, Phillips AN; UK Collaborative HIV Cohort (CHIC) Study.

Lancet HIV 2017; 4:e295-e302.

 

Improved kidney function in patients who switch their protease inhibitor from atazanavir or lopinavir to darunavir.

Jose S, Nelson M, Phillips A, Chadwick D, Trevelion R, Jones R, Williams DI, Hamzah L, Sabin CA, Post FA; UK CHIC study.

AIDS 2017; 31:485-492.

 

Growing up with perinatal HIV: changes in clinical outcomes before and after transfer to adult care in the UK.

Judd A, Colliins IJ, Parrott F , Hill T, Jose S, Ford D, Asad H, Gibb DM, Sabin C.

Int AIDS Soc 2017, 20(Suppl 3):21577.

 

Development and application of a new measure of engagement in out-patient HIV care.

Howarth AR, Burns FM, Apea V, Jose S, Hill T, Delpech VC, Evans A, Mercer CH, Michie S, Morris S, Sachikonye M, Sabin C; REACH study; UK Collaborative HIV Cohort (UK CHIC) Study.

HIV Med 2017; 18:267-274.

 

Association between engagement in-care and mortality in HIV-positive persons.

Sabin CA, Howarth A, Jose S, Hill T, Apea V, Morris S, Burns F; UK CHIC Study Group and the REACH Study Group.

AIDS 2017; 31:653-660.

 

REACH: a mixed-methods study to investigate the measurement, prediction and improvement of retention and engagement in outpatient HIV care. (Final Report)

Howarth A, Apea V, Michie S, Morris S, Sachikonye M, Mercer C, Evans A, Delpech V, Sabin C and Burns F.

Health Services and Delivery Research Volume: 5, Issue:13. March 2017. 

https://www.journalslibrary.nihr.ac.uk/hsdr/hsdr05130/#/abstract

 

A tale of two countries: all-cause mortality among people living with HIV and receiving combination antiretroviral therapy in the UK and Canada.

Patterson S, Jose S, Samji H, Cescon A, Ding E, Zhu J, Anderson J, Burchell AN, Cooper C, Hill T, Hull M, Klein MB, Loutfy M, Martin F, Maschouf N, Montaner J, Nelson M, Raboud J, Rourke SB, Tsoukas C, Hogg RS, Sabin C; Canadian Observational Cohort (CANOC) -  UK Collaborative HIV Cohort (UK CHIC) Collaboration.

HIV Med 2017; 18:655-66.

 

Cirrhosis and liver transplantation in patients co-infected with HIV and hepatitis B or C: and observational cohort study.

Warren-Gash C, Childs K, Thornton A, Bhagani S, Demma S, Srivastava A, Leen C, Agarwal K, Rodger AJ, Sabin CA, Joint UK CHIC and liver transplant advisory group.

Infection 2017; 45:215-220.

 

An association between K65R and HIV-1 subtype C viruses in patients treated with multiple NRTIs.

Smit E, White E, Clark D, Churchill D, Zhang H, Collins S, Pillay D, Sabin C, Nelson M, Winston A, Jose S, Tostevin A, Dunn DT. UK HIV Drug Resistance Database and the UK Collaborative HIV Cohort.

Antimicrob Chemother 2017; 72:2075-82. doi: 10.1093/jac/dkx091. PMID: 28379449

 

Effect of immediate initiation of antiretroviral treatment in HIV-positive individuals aged 50 years or older.

Lodi, S, Costagliola D, Sabin C, Del Amo J, Logan R, Abgrall S, Reiss P, van Sighem A, Jose S, Blanco JR, Hernando V, Bucher HC, Kovari H, Segura F, Ambrosioni J, Gogos CA, Pantazis N, Dabis F, Vandenhende MA, Meyer L, Seng R, Gill MJ, Krentz H, Phillips AN, Porter K, Grinsztejn B, Pacheco AG, Muga R, Tate J, Justice A, Hernán MA.

J Acquir Immune Defic Syndr 2017; 76:311-318. doi: 10.1097/0000000000001498. QAI. PMID: 28746165

 

Reference curves for CD4 T-cell count response to combination antiretroviral therapy in HIV-1-infected treatment naïve patients.

Standard Reference Distribution of CD4 Response to HAART Project Team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord.

HIV Med 2017; 18:33-44. doi: 10.1111/hiv.12389. PMID: 27625009

 

Chronic hepatitis B and C virus infection and risk for non-Hodgkin lymphoma in HIV-infected patients; a cohort study.

Hepatitis coinfection and non Hodgkin lymphoma project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord.

Ann Intern Med 2017; 166:9-17. doi: 10.7326/M16-0240. PMID: 27750294

 

Comparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study.

HIV-CAUSAL Collaboration; Centers for AIDS Research Network of Integrated Clinical Systems.

Lancet HIV 2017; Jun;4(6):e251-e259.

 

2016 publications

 

Predicting virological decay in patients starting combination antiretroviral therapy.

Hughes RA; UK Collaborative HIV Cohort (UK CHIC) Writing Committee.

AIDS 2016; 30:1817-27.

 

Can hepatitis C virus (HCV) direct-acting antiretroviral treatment as prevention reverse the HCV epidemic among men who have sex with men in the United Kingdom? Epidemiological and modeling insights.

Martin NK, Thornton A, Hickman M, Sabin C, Nelson M, Cooke GS, Martin TC, Delpech V, Ruf M, Price H, Azad Y, Thomson EC, VIckerman P.

Clin Infect Dis 2016; 62:1072-80.

 

Mortality of treated HIV-1 positive individuals according to viral subtype in Europe and Canada: collaborative cohort analysis.

Antiretroviral Therapy Cohort Collaboration (ART-CC), Canadian Observational Cohort Collaboration (CANOC), The UK Collaborative HIV Cohort Study (UK CHIC), the Collaboration of Obserational HIV Epidemiological Research in Europe (COHERE).

AIDS 2016; 30:503-13.

 

Clinical characteristics and outcomes of HIV-associated immune complex kidney disease.

Booth JW, Hamzah L, Jose S, Horsfield C, O’Donnell P, McAdoo S, Kumar EA, Turner-Stokes T, Khatib N, Das P, Naftalin C, Mackie N, Kingdon E, Williams D, Hendry BM, Sabin C, Jones R, Levy J, Hilton R, Connolly J, Post FA; HIV/CKD Study and the UK CHIC Study.

Nephrol Dial Transplant 2016; 31:2099-2107.

 

Virological failure and development of new resistance mutations according to CD4 count at combination antiretroviral therapy initiation.

Jose S, Quinn K, Dunn D, Cox A, Sabin C, Fidler S,: UK CHIC and UK HDRD Steering Committees.

HIV Med 2016; 17:368-72.

 

HIV-1 drug resistance mutations emerging on darunavir therapy in PI-naïve and –experienced patients in the UK.

El Bouzidi K, White E, Mbisa JL, Sabin CA, Phillips AN, Mackie N, Pozniak AL, Tostevin A, Pillay D, Dunn DT; UK HIV Drug Resistance Database (UK HDRD) and UK Collaborative HIV Cohort (UK CHIC) Study Steering Committees.

J Antimicrobial Chemother 2016; 71:3487-94.

 

No evidence that HIV-1 subtype C infection compromises the efficacy of tenofovir-containing regimens: cohort study in the United Kingdom.

White E, Smit E, Churchill D, Collins S, Booth C, Tostevin A, Sabin C,  Pillay D, Dunn DT; UK HIV Drug Resistance Database and the UK Collaborative HIV Cohort Study.

J Infect Dis 2016; 214:1302-08. doi: 10.1093/infdis/jiw213. PMID: 27732929  

 

Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen.

De Luca A, Flandre P, Dunn D, Zazzi M, Wensing A, Santoro MM, Gunthard HF, Wittkop L, Kordossis T, Garcia F, Castagna A, Cozzi-Lepri A, Churchill D, De Wit S, Brockmeyer NH, Imaz A, Mussini C, Obel N, Perno CF, et al.; CHAIN and COHERE in EuroCoord.

J Antimicrob Chemother 2016; 71:1352-60. doi: 10.1093/jac/dkv465. PMID: 26825119

 

Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study.

The TenoRes Study Group.

Lancet Infect Dis 2016; 16:565-575. doi: 10.1016/S1473-3099(15)00536-8. PMID: 26831472

 

Efaviranz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: A prospective study of HIV-positive individuals.

Cain LE, Caniglia EC, Phillips A, Olson A, Muga R, Pérez-Hoyos S, Abgrall S, Costagliola D, Rubio R, Jarrín I, Bucher H, Fehr J, van Sighem A, Reiss P, Dabis F, Vandenhende MA, Logan R, Robins J, Sterne JA, Justice A, Tate J, Touloumi G, Paparizos V, Esteve A, Casabona J, Seng R , Meyer L, Jose S, Sabin C, Hernán MA; HIV-CAUSAL Collaboration.

Medicine (Baltimore) 2016 Oct;95(41):e5133. doi: 10.1097/MD.0000000000005133.   PMID: 27741139

 

 

2015 publications

 

Pregnancy is associated with elevation of liver enzymes in HIV-positive women on antiretroviral therapy.

Huntington S, Thorne C, Newell ML, Anderson J, Taylor GP, Pillay D, Hill T, Tookey PA, Sabin C; the UK Collaborative HIV Cohort (UK CHIC) Study, the UK and Ireland National Study of HIV in Pregnancy, Childhood (NSHPC).

AIDS 2015; 29:801-9.

 

Host, disease, and antiretroviral factors are associated with normalization of the CD4:CD8 ratio after initiating antiretroviral therapy.

Winston A, Jose S, Fisher M, Walsh J, Nelson M, Gilson R, Post F, Johnson M, Leen C, Chadwick D, Hay P, Pritchard J, Tariq A, Sabin C; UK Collaborative HIV Cohort Study.

J Allergy Clin Immunol 2015; 136:1682-85. doi: 10.1016/j.jaci.2015.05.047. PMID: 26253341

 

The risk of viral rebound in the year after delivery in women remaining on antiretroviral therapy.

Huntington S, Thorne C, Newell ML, Anderson J, Talyor GP, Pillay D, Hill T, Tookey PA, Sabin C; UK Collaborative HIV Cohort (UK CHIC) Study and the UK and Ireland National Study of HIV in Pregnancy and Childhood (NSHPC).

AIDS 2015; 29:2269-78.

 

Renal tubular disease in the era of combination antiretroviral therapy.

Hamzah L, Booth JW, Jose S, McAdoo SP, Kumar EA, O’Donnell P, Hilton R, Sabin C, Williams DI, Jones R, Post FA; HIV/CKD Study.

AIDS 2015; 29;1831-6.

 

Boosted lopinavir-versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.

HIV-CAUSAL Collaboration, Cain LE, Phillips A, Olson A, Sabin C, Jose S, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, Reiss P, Young J, Fehr J, Touloumi G, Paparizos V, Esteve A, Casabona J, Monge S, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Dabis F, Vandenhende MA, Abgrall S, Costagliola D, Hernán MA.

Clin Infect Dis 2015; 60:1262-1268. doi: 10.1093/cid/ciu1167. PMID: 25567330

 

Efavirenz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: A prospective study of HIV-positive individuals.

Cain LE, Caniglia EC, Phillips A, Olson A, Muga R, Pérez-Hoyos S, Abgrall S, Costagliola D, Rubio R, Jarrín I, Bucher H, Fehr J, van Sighem A, Reiss P, Dabis F, Vandenhende MA, Logan R, Robins J, Sterne JAC, Justice A, Tate J, Touloumi G, Paparizos V, Esteve A, Casabona J, Seng R, Meyer L, Jose S, Sabin C, Hernán MA; on behalf of the HIV-CAUSAL Collaboration.

Medicine (Baltimore) 2016; 95(41), e5133. doi: 10.1097/MD.0000000000005133.  PMID: 27741139

 

 

2014 publications

 

End-stage kidney disease and kidney transplantation in HIV positive patients: and observational cohort study.

Gathogo E, Jose S, Jones R, Levy JB, Mackie NE, Booth J, Connolly J, Johnson M, Leen C, Williams D, Sabin CA, Post FA.

J Acquir Immune Defic Syndr 2014; 67:177-80.

 

Laboratory adverse events and discontinuation of therapy according to CD4+ cell count at the start of antiretroviral therapy.

Jose S, Quinn K, Hill T, Leen C, Walsh J, Hay P, Fisher M, Post F, Nelson M, Gompels N, Johnson M, Chadwick D, Gilson R, Sabin C, Fidler S; UK CHIC Steering Committee.

AIDS 2014; 28:1333-9.

 

The effects of age on associations between markers of HIV progresion and markers of metabolic function including albumin, haemoglobin and lipid concentrations.

Samuel M, Jose S, Winston A, Nelson M, Johnson M, Chadwick D, Fisher M, Leen C, Gompels M, Gilson R, Post F, Hay P, Sabin C; UK Collaborative HIV Cohort Study (UK CHIC).

HIV Med 2014; 15:311-6. doi: 10.1111/hiv.12103. PMID: 24245861

 

Failure to achieve a CD4+ cell count response on combination antiretroviral therapy despite consistent viral load suppression.

O’Connor JL, Smith CJ, Lampe FC, Hill T, Gompels M, Hay P, Chadwick D, Fisher M, Ainsworth J, Gilson R, Mackie N, Anderson J,Orkin C, Nelson M, Kegg S, Leen C, Palfreeman A, Post F, Johnson M, Sabin CA, Phillips AN; UK Collaborative HIV Cohort (UK CHIC Study Steering Committee.

AIDS 2014; 28:919-24.

 

Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy: UK cohort study.

May MT, Gompels M, Delpech V, Porter K, Orkin C, Kegg S, Hay P, Johnson M, Palfreeman A, Gilson R, Chadwick K, Martin F, Hill T, Walsh J, Post F, Fisher M, Ainsworth  J, Jose S, Leen C, Nelson M, Anderson J, Sabin C; for the UK Collaborative HIV Cohort (UK CHIC) Study.

AIDS 2014; 28:1193-202.

 

Response to antiretroviral therapy (ART): comparing women with previous use of zidovudine monotherapy (ZDVm) in pregnancy with  ART naïve women.

Huntington S, Thorne C, Anderson J, Newell ML, Taylor GP, Pillay D, Hill T, Tookey P, Sabin C; UK Collaborative HIV Cohort (UK CHIC) Study; National Study of HIV in Pregnancy and Childhood  (NSHPC).

BMC Infect Dis 2014; 14:127.

 

The contribution of viral genotype to plasma viral set-point in HIV infection.

Hodcroft E, Hadfield JD, Fearnhill E, Phillips A, Dunn D, O’Shea S, Pillay D, Leigh Brown AJ; UK HIV Drug Resistance Database; UK CHIC Study.

PLos Pathog 2014 May 1; doi: 10.1371/journal.ppat.1004112. eCollection 2014.

 

The emergence of drug resistant HIV variants at virological failure of HAART combinations containing efavirenz, tenofovir, and lamivudine or emtricitabine within the UK Collaborative HIV Cohort.

Bulteel N, Bansi-Matharu L, Churchill D, Dunn D, Bibby D, Hill T, Sabin C, Nelson M; UK Collaborative HIV Cohort (CHIC) Study Group; UK HIV Drug Resistance Database (UK HDRD) Study Group.

J Infect 2014; 68:77-84.

 

Factors associated with short-term changes in HIV viral load and CD4+ cell count in antiretroviral-naïve individuals.

The Natural History Project Working Group for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord.

AIDS 2014; 28:1351-6. doi: 10.1097/QAD.0000000000000224.   PMID: 24959963

 

The effects of HIV-1 subtype and ethnicity on the rate of CD4 cell count decline in patients naive to antiretroviral therapy: a Canadian-European collaborative retrospective cohort study.

Klein MB, Young J, Dunn D, Lederberger B, Sabin C, Cozzi-Lepri A, Dabis Fl, Harrigan R, Tan DH, Walmsley S, Gill J, Cooper C, Scherrer AU, Mocroft A, Hogg RS, Smaill F; Canadian-European Clade Collaboration.

CMAJ Open 2014; 2:E318-29. doi: 10.9778/cmajo.20140017. PMID: 25485259

 

 

2013 publications

 

Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring.

Winston A, Jose S, Gibbons S, Back D, Stohr W, Post F, Fisher M, Gazzard B, Nelson M, Gilson R, Orkin C, Johnson M, Palfreeman A, Chadwick D, Leen C, Schwenk A, Anderson J, Gompels M, Dunn D, Khoo S, Sabin C; UK Collaborative HIV Cohort Study.

J Antimicrob Chemother 2013; 68:1354-9.

 

Predictors of pregnancy and changes in pregnancy incidence among HIV-positive women accessing HIV clinical care.

Huntigton SE, Thorne C, Bansi LK, Anderson J, Newell ML, Taylor GP, Pillay D, Hill T, Tookey PA, Sabin CA; UK Collaborative HIV Cohort (UK CHIC) Study and the National Study of HIV in Pregnancy and Childhood (NSHPC).

AIDS 2013; 27:95-103.

 

HLA B*5701 status, disease progression and response to antiretroviral therapy.

UK Collaborative HIV Cohort Study Steering Committee.

AIDS 2013; 27:2587-92.

 

The impact of HIV-1 reverse transcriptase polymorphisms on responses to first-line nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-1-infected adults.

Mackie NE, Dunn DT, Dolling D, Garvey L, Harrison L, Fearnhill E, Tilston P, Sabin C, Geretti AM; UK  HIV Drug Resistance Database; UK CHIC study.

AIDS 2013; 27:2245-53.

 

Low frequency of gentypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort study.

Dolling DI, Dunn DT, Sutherland KA, Pillay D, Mbisa JL, Parry CM, Post FA, Sabin CA, Cane PA; on behalf of the UK HIV Drug Resistance Database (UKHDRD) and the UK Collaborative HIV Cohort Study (UK CHIC).

J Antimicrob Chemother 2013: 68:2339-43.

 

Second-line protease inhibitor-based antiretroviral therapy after non-nucleoside reverse transcriptase inhibitor failure: the effect of a nucleoside backbone.

Waters L, Bansi L, Asboe D, Pozniak A, Smit E, Orkin C, Fearnhill E, Dunn D, Phillips A; UK CHIC Study; UK HIV Drug Resistance Database.

Antivir Ther 2013, 18:213-9.

 

Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in western Europe.

De Luca A, Dunn D, Zazzi M, Camacho R, Torti C, Fanti I, Kaiser R, Sonnerborg A, Codoner FM, Van Laethem K, Vandamme A-M, Bansi L, Ghisetti V, van de Vijver DAMC, Asboe D, Prosperi MCF, Di Giambenedetto S for the SEHERE collaboration in CHAIN.

J Infect Dis 2013; 207:1216-20.

 

Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with or without thymidine analogues.

Santoro MM, Sabin C, Forbici F, Bansi L, Dunn D, Fearnhill E, Boumis E, Nicastri E, Antinori A, Palamara G, Callegaro A, Francisci D, Zoncada A, Maggiolo F, Zazzi M, Perno CF, Ceccherini-Silberstein F, Mussini C.

HIV Med 2013; 14:571-7.

 

 

2012 publications

 

Hepatitis B virus infection in HIV-positive individuals in the UK collaborative HIV cohort (UK CHIC) study.

Price H, Bansi L, Sabin CA, Bhagani S, Burroughs A, Chadwick D, Dunn D, Fisher M, Main J, Nelson M, Pillay D, Rodger A, Taylor C, Gilson R; UK Collaborative HIV Cohort Hepatitis group, Steering Committee.

PLoS One 2012;7(11):e49314. doi: 10.1371/journal.pone.0049314.

 

Using two on-going HIV studies to obtain clinical data from before, during and after pregnancy for HIV-positive women.

Huntington SE, Bansi LK, Thorne C, Anderson J, Newell ML, Taylor GP, Pillay D, Hill T, Tookey PA, Sabin CA; on behalf of the UK Collaborative HIV Cohort (UK CHIC) Study and the National Study of HIV in Pregnancy and Childhood (NSHPC).

BMC Med Res Methodol 2012; 12:110.

 

Does discordancy between the CD4 count and CD4 percentage in HIV-positive individuals matter influence outcomes on highly active antiretroviral therapy?

Gompels M, Dunn DT, Phillips A, Dooley D, De Burgh Thomas A, Anderson J, Post F, Pillay D, Gazzard B, Hill T, Johnson M, Gilson R, Bansi L, Easterbrook P, Fisher M, Walsh J, Orkin C, Ainsworth J, Leen C, Sabin C; for the UK CHIC Study (Appendix).

J Infect Dis 2012; 205:540-7.

 

Baseline kidney function as predictor of mortality and kidney disease progression in HIV-positive patients.

Ibrahim F, Hamzah L, Jones R, Nitsch D, Sabin C, Post FA: UK Collaborative HIV Cohort (CHIC)/CKD Study Group.

Am J Kidney Dis 2012; 60:539-47.

 

Biomarkers measured to monitor safety in people on ART and risk of mortality.

Bansi L, Gazzard B, Post F, Phillips A, Johnson M, Hill T, Gilson R, Leen C, Walsh J, Fisher M, Sabin C; for the UK Collaborative HIV Cohort (CHIC) Study.

J Acquir Immune Defic Syndr 2012; 60:51-58.

 

Comparison of CKD-EPI and MDRD to estimate baseline renal function in HIV-positive patients.

Ibrahim F, Hamzah L, Jones R, Nitsch D, Sabin C, Post FA; on behalf of the UK CHIC/CKD study group.

Nephrol Dial Transplant 2012; 27:2291-7.

 

Non-uptake of highly active antiretroviral therapy among patients with a CD4 count < 350 cells/uL in the UK.

Kober C, Johnson M, Fisher M, Hill T, Anderson J, Bansi L, Gompels M, Palfreeman A, Dunn D, Gazzard B, Gilson R, Post F, Philips AN, Walsh J, Orkin C, Delpech V, Ainsworth J, Leen C, Sabin CA; UK Collaborative HIV Cohort (CHIC) Study.

HIV Med 2012; 13:73-8.

 

Uptake and outcome of combination antiretroviral therapy (cART) in men who have sex with men according to ethnic group: the UK CHIC Study.

Sethi G.

J Acquir Immune Defic Syndr 2012; 59:523-29.

 

Evaluating the extent of potential resistance to pre-exposure prophylaxis within the UK HIV-1-infectious population of men who have sex with men.

Dolling D, Phillips A, Delpech V, Pillay D, Cane P, Crook A, Shepherd J, Fearnhill E, Hill T, Dunn D; on behalf of the UK HIV Drug Resistance Database and the UK Collaborative HIV Cohort (UK CHIC) Study.

HIV Med 2012; 13:309-14.

 

Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor.

Barber TJ, Harrison L, Asboe D, Williams I, Kirk S, Gilson R, Bansi L, Pillay D, Dunn D; on behalf of the UK HIV Drug Resistance Database and the UK Collaborative HIV Cohort (UK CHIC) Study Steering Committees.

J Antimicrob Chemother 2012: 67:995-1000.

 

CD4 cell count and the risk of AIDS or death in HIV-infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE.

Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord.

PLoS Med2012;9(3):e1001194. doi: 10.1371/journal.pmed.1001194.

 

Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug-experienced people with HIV in Europe.

The Pursuing Later Treatment Options II (PLATO II) project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Group.

J Acquir Immune Defic Syndr 2012; 59:294-9.

 

 

2011 publications

 

Treatment switches during pregnancy among HIV-positive women on antiretroviral therapy at conception.

Huntington SE, Bansi LK, Thorne C, Anderson J, Newell ML, Taylor GP, Pillay D, Hill T, Tookey PA, Sabin CA; UK Collaborative HIV Cohort (UK CHIC) Study and the National Study of HIV in Pregnancy and Childhood (NSHPC).

AIDS 2011; 25:1647-55.

 

Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study.

May M, Gompels M, Delpech V, Porter K, Post F, Johnson M, Dunn D, Palfreeman A, Gilson R, Gazzard B, Hill T, Walsh J, Fisher M, Orkin C, Ainsworth J, Bansi L, Phillips A, Leen C, Nelson M, Anderson J, Sabin C.

BMJ 2011; Oct 11;343:d6016. doi: 10.1136/bmj.d6016.

 

Antiretroviral therapy CNS penetration and HIV-1 associated CNS disease.

L Garvey, A Winston, J Walsh, F Post, K Porter, B Gazzard, M Fisher, C Leen, D Pillay, T Hill, M Johnson, R Gilson, J Anderson, P Easterbrook, L Bansi, C Orkin, J Ainsworth, A Palfreeman, M Gompels, AN Phillips, CA Sabin; for the UK CHIC Study.

Neurology 2011; 76:693-700.

 

Outcomes in the first year after initiation of first-line (HAART) among heterosexual men and women in the UK CHIC Study.

Barber TJ, Geretti AM, Anderson J, Schwenk A, Phillips AN, Bansi L, Gilson R, Hill T, Walsh J, Fisher M, Johnson M, Post F, Easterbrook P, Gazzard B, Palfreeman A, Orkin C, Leen C, Gompels M, Dunn D, Delpech V, Pillay D, Sabin CA; UK CHIC Study.

Antivir Ther 2011; 16:805-14.

 

HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era.

The UK Collaborative HIV Cohort (CHIC) Study Steering Committee.

Eur J Neur 2011; 18:527-534.

 

When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illnesses in HIV-infected persons in developed countries: an observational study.

The HIV-CAUSAL Collaboration.

Ann Intern Med 2011; 154:509-515.

 

Long term trends in CD4 counts and impact of viral failure in individuals starting antiretroviral therapy: UK Collaborative HIV cohort (CHIC) study.

Hughes R, Sterne J, Walsh J, Bansi L, Gilson R, Orkin C, Hill T, Ainsworth J, Anderson J, Gompels M, Dunn D, Johnson M, Phillips A, Pillay D, Leen C, Easterbrook P, Gazzard B, Fisher M, Sabin C.

HIV Med 2011; 12:583-93.

 

Responses to HAART and clinical events in patients with a low CD4 count: late presenters vs. late starters.

Waters L, Fisher M, Anderson J, Wood C, Delpech V, Hill T, Walsh J, Orkin C, Bansi L, Gompels M, Phillips A, Johnson M, Gilson R, Easterbrook P, Leen C, Porter K, Gazzard B, Sabin C; for the UK CHIC Steering Committee.

HIV Med 2011; 12:289-198.

 

The impact of HIV drug resistance testing on changes to treatment.

L Bansi, C Smith, A Phillips, S Kirk, AM Gerretti, M Johnson, N Mackie, F Post, B Gazzard, D Dunn, C Sabin: on behalf of the UK Collaborative HIV Cohort (CHIC) Study and UK Collaborative Group on HIV Drug Resistance (HDRD).

AIDS 2011; 25:603-10.

 

Responses to highly active antiretroviral therapy and clinical events in patients with a low CD4 cell count: late presenters vs. late starters.

Waters L, Fisher M, Anderson J, Wood C, Delpech V, Hill T, Walsh J, Orkin C, Bansi L, Gompels M, Phillips A, Johnson M, Gilson R, Easterbrook P, Leen C, Porter K, Gazzard B, Sabin C; for the UK CHIC Steering Committee.

HIV Med 2011; 12:289-298.

 

Can linear regression modeling help clinicians in the interpretation of genotypic resistance data?  An application to derive a lopinavir-score.

Cozzi-Lepri A, Prosperi MC, Kjær J, Dunn D, Paredes R, Sabin CA, Lundgren JD, Phillips AN, Pillay D, EuroSIDA Study; United Kingdom CHIC/United Kingdom HDRD Study.

PLoS One 2011;6(11):e25665. doi: 10.1371/journal.pone.0025665.

 

The impact of HIV drug resistance testing on changes to treatment.

Bansi L, Smith C, Phillips A, Kirk S, Geretti AM, Johnson M, Mackie N, Post F, Gazzard B, Dunn D, Sabin C; UK Collaborative HIV Cohort (CHIC) Study and the UK Collaborative Group on HIV Drug Resistance (HDRD).

AIDS 2011; 25:603-10.

 

When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illnesses in HIV-infected persons in developed countries: an observational study.

The HIV-CAUSAL Collaboration.

Ann Intern Med 2011; 154:509-515.

 

 

2010 publications

 

Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study.

Study Group on Death Rates at High CD4 Count in Antiretroviral Naïve Patients.

Lancet 2010; 376:340-5.

 

The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals.

HIV-CAUSAL Collaboration.

AIDS 2010; 24:123-37.

 

Triple class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years.

Pursuing Later Treatment Options II (PLATO II) Project Team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE).

Arch Intern Med 2010; 170:410-9.

 

The prevalence of hepatitis C virus (HCV) infection in HIV-positive individuals in the UK - trends in HCV testing and the impact of HCV on HIV treatment outcomes.

J Turner, L Bansi, R Gilson, B Gazzard, J Walsh, D Pillay, C Orkin, A Phillips, P Easterbrook, M Johnson, K Porter, A Schwenk, T Hill, C Leen, J Anderson, M Fisher, C Sabin; on behalf of the UK Collaborative HIV Cohort (UK CHIC) Study.

J Viral Hepat 2010; 17:569-77.

 

Long-term probability of detecting drug-resistant HIV in treatment-naïve patients initiating combination antiretroviral therapy.

UK Collaborative Group on HIV Drug Resistance; UK CHIC Study Group.

Clin Infect Dis 2010; 50:1275-85.

 

Data linkage reduces loss to follow-up in an observational HIV cohort study.

T Hill, L Bansi, C Sabin, A Phillips, D Dunn, J Anderson, P Easterbrook, M Fisher, B Gazzard, R Gilson, M Johnson, C Leen, C Orkin, A Schwenk, J Walsh, A Winston, A Babiker, V Delpech; on behalf of the UK Collaborative HIV Cohort (UK CHIC) Study Group.

J Clin Epidemiol 2010; 63:1101-9.

 

Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populations.

L Bansi, C Sabin, V Delpech, T Hill, M Fisher, J Walsh, T Chadborn, P Easterbrook, R Gilson, M Johnson, K Porter, J Anderson, M Gompels, C Leen, J Ainsworth, C Orkin, M Nelson, B Rice, A Phillips; for the UK Collaborative HIV Cohort (CHIC) Study and the Health Protection Agency.

HIV Med 2010; 11:432-8.

 

Late diagnosis in the HAART era: proposed common definitions and associations with mortality.

The UK Collaborative HIV Cohort (UK CHIC) Steering Committee.

AIDS 2010; 24:723-7.

 

Factors influencing lopinavir and atazanavir plasma concentration.

W Stöhr, D Back, D Dunn, C Sabin, A Winston, R Gilson, D Pillay, T Hill, J Ainsworth, B Gazzard, C Leen, L Bansi, M Fisher, C Orkin, J Anderson, M Johnson, P Easterbrook, S Gibbons, S Khoo; UK CHIC Steering Committee.

J Antimicrob Chemother 2010; 65:129-37.

 

Discordant responses on starting highly active antiretroviral therapy: suboptimal CD4 increases despite early viral suppression in the UK Collaborative HIV Cohort (UK CHIC) Study.

RJ Gilson, SL Man, A Copas, A Rider, S Forsyth, T Hill, L Bansi, K Porter, B Gazzard, C Orkin, D Pillay, A Schwenk, M Johnson, P Easterbrook, J Walsh, M Fisher, C Leen, J Anderson, CA Sabin; UK Collaborative HIV Cohort Study Group.

HIV Med 2010; 11:152-60.

 

Epidemiology of non-B clade forms of HIV-1 in men who have sex with men in the UK.

Fox J, Castro H, Kay S, McClure M, Weber JN, Fidler S; UK Collaborative Group on HIV Drug Resistance.

AIDS 2010; 24:2397-401.

 

HIV type-1 drug resistance in antiretroviral treatment-naïve adults infected with non-B subtype virus in the UK.

Chilton DN, Castro H, Lattimore S, Harrison LJ, Fearnhill E, Delpech V, Rice B, Pillay D, Dunn DT; UK Collaborative Group on HIV Drug Resistance.

Antivir Ther 2010; 15:985-91.

 

Impact of transmitted drug-resistance on treatment selection and outcome of first-line Highly Active Antiretroviral Therapy (HAART).

Bansi L, Geretti AM, Dunn D, Hill T, Green H, Fearnhill E, Gazzard B, Nelson M, Porter K, Phillips A, Sabin C; UK Collaborative Group on HIV Drug Resistance and UK Collaborative HIV Cohort (CHIC) Study.

J Acquir Immune Defic Syndr 2010; 53:633-9.

 

The effect of transmitted HIV-1 drug resistance on pre-therapy viral load.

Harrison L, Castro H, Cane P, Pillay D, Booth C, Phillips A, Geretti AM, Dunn D; UK Collaborative Group on HIV Drug Resistance and the UK Collaborative HIV Cohort Study (UK CHIC).

AIDS 2010; 24:1917-22.

 

Long-term probability of detecting drug-resistant HIV in treatment-naive patients initiating combination antiretroviral therapy.

The UK Collaborative Group on HIV Drug Resistance and UK CHIC Study Group.

Clin Infect Dis 2010; 50:1275-85.

 

Positive and negative drug selection pressures on the N348I connection domain mutation: new insights from in vivo data.

H Price, D Asboe, A Pozniak, B Gazzard, E Fearnhill, D Pillay, D Dunn; UK Collaborative Group on HIV Drug Resistance, UK Collaborative HIV Cohort Study.

Antiviral Therapy 2010; 15:203-11.

 

Antiretroviral drug resistance in HIV-1-infected patients with low-level viremia.

NE Mackie, AN Phillips, S Kaye, C Booth, AM Geretti on behalf of the UK Resistance Database and the UK Collaborative HIV Cohort Study.

J Infect Dis 2010; 201:1303-7.

 

Impact of transmitted drug-resistance on treatment selection and outcome of first-line highly active antiretroviral therapy (HAART).

Bansi L, Geretti AM, Dunn D, Hill T, Green H, Fearnhill E, Gazzard B, Nelson M, Porter K, Phillips A, Sabin C; UK Collaborative Group on HIV Drug Resistance and UK Collaborative HIV Cohort (CHIC) Study.

J Acquir Immune Defic Syndr 2010; 53:633-9.

 

Triple class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years.

Pursuing Later Treatment Options II (PLATO II) Project Team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE).

Arch Intern Med 2010; 170:410-9.

 

Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study.

Study Group on Death Rates at High CD4 Count in Antiretroviral Naïve Patients, RK Lodwick, CA Sabin, K Porter, B Ledergerber, A van Sighem, A Cozzi-Lepri, P Khaykin, A Mocroft, L Jacobson, S De Wit, N Obel, A Casgagna, JC Wasmuth, J Gill, MB Klein, S Gange, M Riera, C Mussini, F Gutierrez, G Touloumi, P Carrieri, JL Guest, NH Brockmeyer, AN Phillips.

Lancet 2010; 376:340-5.

 

The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals.

HIV-CAUSAL Collaboration.

AIDS 2010; 24:123-37.

 

 

2009 publications

 

Clinical epidemiology of HIV-associated end-stage renal failure in the UK.

L Bansi, A Hughes, S Bhagani, NE Mackie, C Leen, J Levy, S Edwards, J Connolly, SG Holt, BM Hendry, C Sabin, FA Post; UK CHIC/ESRF study group.

AIDS 2009; 23:2517-21.

 

Is 1 alanine transaminase >200 IU enough to define an alanine transaminase flare in HIV-infected populations? A new definition derived from a large cohort study.

L Bansi, J Turner, R Gilson, F Post, B Gazzard, C Leen, J Anderson, K Porter, T Hill, M Fisher, J Ainsworth, D Pillay, M Johnson, A Winston, C Orkin, P Easterbrook, A Phillips, C Sabin; UK Collaborative HIV Cohort Study.

J Acquir Immune Defic Syndr 2009; 52:391-6.

 

CD4 counts and the risk of systemic non-Hodgkin’s lymphoma in individuals with HIV in the UK.

M Bower, M Fisher, T Hill, I Reeves, J Walsh, C Orkin, AN Phillips, L Bansi, R Gilson, P Easterbrook, M Johnson, B Gazzard, C Leen, D Pillay, A Schwenk, J Anderson, K Porter, Gompels, and CA Sabin for the UK CHIC Steering Committee.

Haematologica 2009; 94:875-80.

 

The associations between age and the development of laboratory abnormalities and treatment discontinuation for reasons other than virological failure in the first year of highly active antiretroviral therapy.

C Sabin, C Smith, V Delpech, J Anderson, L Bansi, R Gilson, A Schwenk, C Leen, B Gazzard, K Porter, N Mackie, M Fisher, C Orkin, M Johnson, P Easterbrook, T Hill, A Phillips; on behalf of the UK Collaborative HIV Cohort (CHIC) Study.

HIV Med 2009; 10:35-43.

 

The effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy (HAART).

AM Geretti, L Harrison, H Green, C Sabin, T Hill, E Fearnhill, D Pillay, D Dunn on behalf of the UK Collaborative Group on HIV Drug Resistance and the UK Collaborative HIV Cohort Study (UK CHIC).

Clin Infect Dis 2009; 48: 1296-305.

 

Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy.

AM Kesselring, FW Wit, CA Sabin, JD Lundgren, MJ Gill, JM Gatell, A Raunch, JS Montaner, F de Wolf, P Reiss, A Mocroft; Nevirapine Toxicity Multicohort Collaboration.

AIDS 2009; 23:1689-99.

 

Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study.

Collaboration of Observational HIV Epidemiology Research Europe (COHERE) Study Group.

Antivir Ther 2009; 14:1065-74.

 

Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy.

Collaboration of Observational HIV Epidemiology Research Europe (COHERE) study group.

AIDS 2009; 23:2029-37.

 

 

2008 publications

 

Treatment switches after viral rebound in HIV-infected adults starting antiretroviral therapy: multicentre cohort study.

United Kingdom Collaborative HIV Cohort Study, KJ Lee, D Dunn, K Porter, R Gilson, L Bansi, T Hill, AN Phillips, CA Sabin, A Schwenk, C Leen, V Delpech, J Anderson, B Gazzard, M Johnson, P Easterbrook, J Walsh, M Fisher, C Orkin. 

AIDS 2008; 22:1943-50.

 

Factors Influencing Efavirenz and Nevirapine Plasma Concentration: Effect of Ethnicity, Weight, and Co-Medication.

W Stöhr, D Back, D Dunn, C Sabin, A Winston, R Gilson, D Pillay, T Hill, J Ainsworth, A Pozniak, C Leen, L Bansi, M Fisher, C Orkin, J Anderson, M Johnson, P Easterbrook, S Gibbons, S Khoo; Liverpool TDM database; UK CHIC Study.

Antivir Ther 2008; 13:675-85.

 

Changes in outcome of persons initiating highly active antiretroviral therapy at a CD4 count of less than 50 cells/mm3.

Porter K, Walker S, Hill T, Anderson J, Leen C, Johnson M, Gazzard B, Walsh J, Fisher M, Orkin C, Schwenk A, Gilson R, Easterbrook P, Delpech V, Sabin CA; UK CHIC Study Group.

J Acquir Immune Defic Syndr 2008; 47:202-5.

 

Patterns and predictors of the use of different antiretroviral drug regimes at treatment initiation in the UK.

Easterbrook PJ, Phillips AN, Hill T, Matthias R, Fisher M, Gazzard B, Gilson R, Scullard G,

Johnson M, Dunn DT, Orkin C, Anderson J, Schwenk A, Leen C, and Sabin CA; on behalf of the UK Collaborative HIV Cohort (CHIC) Study Steering Committee.

HIV Med 2008; 9:47-56.

 

Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression?

Bansi LK, Benzie AA, Phillips AN, Portsmouth S, Hill T, Leen C, Schwenk A, Johnson M, Anderson J, Gilson R, Easterbrook P, Gazzard B, Fisher M, Orkin C, Porter K, Pillay D, Taylor GP, Walsh JC, Sabin CA; UK Collaborative HIV Cohort (UK CHIC) Study.

AIDS 2008; 22:349-56.

 

What is the risk of mortality following diagnosis of multidrug-resistant HIV-1?

D Grover, A Copas, H Green, SG Edwards, DT Dunn, C Sabin, A Phillips, E Allen, D Pillay; UK Collaborative Group on HIV Drug Resistance and UK Collaborative HIV Cohort Study (UK CHIC).

J Antimicrob Chemother 2008; 61: 705-13.

 

Population trends in the prevalence and patterns of protease resistance related to exposure to unboosted and boosted protease inhibitors.

UK Collaborative Group on HIV Drug Resistance and UK Collaborative HIV Cohort Study.

Antiviral Therapy 2008; 13:771-7.

 

Response to combination antiretroviral therapy: variation by age.

Collaboration of Observational HIV Epidemiological Reserch Europe (COHERE) Study Group.

AIDS 2008; 22:1463-73.

 

 

2007 publications

 

HIV diagnosis at CD4 count above 500 cells/mm3 and progression to below 350 cells/mm3 without antiretroviral therapy.

UK Collaborative HIV Cohort (CHIC) Study Steering Committee.

J Acquir Immune Defic Syndr 2007; 46:275-8.

 

Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study.

Phillips AN, Leen C, Wilson A, Anderson J, Dunn D, Schwenk A, Orkin C, Hill T, Fisher M, Walsh J, Pillay D, Bansi L, Gazzard B, Easterbrook P, Gilson R, Johnson M, Sabin CA; UK Collaborative HIV Cohort (CHIC) Study.

Lancet 2007; 370:1923-8.

 

Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naïve individuals with high CD4 count.

The UK Collaborative HIV Cohort (CHIC) Study Steering Committee.

(Analysis and writing committee/UK CHIC steering committee: Phillips AN, Gazzard B, Gilson R, Easterbrook P, Johnson M, Walsh J, Leen C, Fisher M, Orkin C, Anderson J, Pillay D, Delpech V, Sabin C, Schwenk A, Dunn D, Gompels M, Hill T, Porter K, Babiker A; UK Collaborative HIV Cohort Study.)

AIDS 2007; 21:1717-1721.

 

Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failures.

Benzie AA, Bansi LK, Sabin CA, Portsmouth S, Hill T, Johnson M, Gilson R, Easterbrook P, Gazzard B, Fisher M, Orkin C, Dunn D, Delpech V, Taylor GP, Walsh JC, and Phillips AN on behalf of the UK Collaborative HIV Cohort (CHIC) Study.

AIDS 2007; 21:1423-1430.

 

CD4 cell count and initiation of ART: Trends in seven UK centres 1997-2003.

Stöhr W, Dunn DT, Porter K, Hill T, Gazzard B, Walsh J, Gilson R, Easterbrook P, Fisher M, Johnson MA, Delpech VC, Phillips AN and Sabin CA, on behalf of the UK CHIC Study.

HIV Medicine 2007; 8(3): 135-141.

 

Fourth report from the UK HIV Drug Resistance Database.

Health Protection Report (August 2007) Vol. 1 No. 31. [HPA link]

 

Emergence of the H208Y mutation in the reverse transcriptase (RT) of HIV-1 in association with nucleoside RT inhibitor therapy.

Nebbia G, Sabin CA, Dunn DT, Geretti AM; UK Collaborative Group on HIV Drug Resistance; UK Collaborative HIV Cohort (UK CHIC) Study Group.

J Antimicrob Chemotherapy 2007; 59;1013-6.  

 

Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom.

UK Collaborative Group on HIV Drug Resistance; UK Collaborative HIV Cohort Study; UK Register of HIV Seroconverters.

AIDS 2007; 21:1035-9.

 

Risk of discontinuation of nevirapine due to toxicities in antiretroviral-naïve and –experienced HIV-infected patients with high and low CD4+ T-cell counts.

A Mocroft, S Staszewski, R Weber, J Gatell, J Rockstroh, J Gasiorowski, G Panos, A Monforte, A Rakhmanova, AN Phillips JD Lundgren; EuroSIDA study group.

Antivir Ther 2007; 12:325-33.

 

 

2006 publications

 

Third report from the UK HIV Drug Resistance Database.

HPA CDR Weekly (Jan 2006) Vol. 16 No. 4.

 

 

2005 publications

 

The Rate of Viral Rebound after Attainment of an HIV Load <50 Copies/mL According to Specific Antiretroviral Drugs in Use: Results from a Multicenter Cohort Study.
Smith CJ, Phillips AN, Hill T, Fisher M, Gazzard B, Porter K, Gilson R, Easterbrook P, Matthias R, Scullard G, Johnson MA, Sabin CA; United Kingdom Collaborative HIV Cohort Study Group.

J Infect Dis 2005 Oct 15;192(8):1387-97.

 

Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study.

Sabin CA, Hill T, Lampe F, Matthias R, Bhagani S, Gilson R, Youle MS, Johnson MA, Fisher M, Scullard G, Easterbrook P, Gazzard B, Phillips AN; UK Collaborative HIV Cohort (UK CHIC) Study Group.

BMJ 2005 Mar 26;330(7493):695.

 

Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice.

Phillips AN, Dunn D, Sabin C, Pozniak A, Matthias R, Geretti AM, Clarke J, Churchill D, Williams I, Hill T, Green H, Porter K, Scullard G, Johnson M, Easterbrook P, Gilson R, Fisher M, Loveday C, Gazzard B, Pillay D; UK Collaborative Group on HIV Drug Resistance; UK CHIC Study Group.

AIDS. 2005 Mar 25;19(5):487-94.

 

 

2004 publications

 

The creation of a large UK-based multicentre cohort of HIV-infected individuals: The UK Collaborative HIV Cohort (UK CHIC).

The UK Collaborative HIV Cohort Steering Committee.

HIV Medicine 2004; 5: 115-124.

 

Second report from the UK HIV Drug Resistance Database.

HPA CDR Weekly (Nov 2004) Vol. 14 No. 48.

 

 

2003 publications

 

First report from the UK HIV Drug Resistance Database.

HPA CDR Weekly (Oct 2003) Vol. 13 No. 43